Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tarsus Pharmaceuticals Inc
(NQ:
TARS
)
25.53
+0.22 (+0.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tarsus Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
January 29, 2024
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
December 21, 2023
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.
Via
Investor's Business Daily
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
December 11, 2023
TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Recap: Tarsus Pharmaceuticals Q3 Earnings
November 09, 2023
Via
Benzinga
Earnings Preview: Tarsus Pharmaceuticals
November 08, 2023
Via
Benzinga
Expert Ratings for Tarsus Pharmaceuticals
September 11, 2023
Via
Benzinga
What 6 Analyst Ratings Have To Say About Tarsus Pharmaceuticals
August 14, 2023
Via
Benzinga
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
November 10, 2023
Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results.
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
November 10, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
July 26, 2023
Via
Benzinga
Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging
November 10, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: SYNA) rose sharply on Friday after the company reported better-than-expected...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Friday Session
November 10, 2023
Via
Investor Brand Network
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
November 09, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
November 01, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Earnings Scheduled For November 9, 2023
November 09, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
Via
Benzinga
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
September 06, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Present at Upcoming Investor Conferences
August 30, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
August 24, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
August 10, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
August 01, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
July 31, 2023
Via
Benzinga
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
July 31, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown
July 25, 2023
The FDA approved Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) Xdemvy (lotilaner ophthalmic solution) 0.25% for
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 25, 2023
Via
Benzinga
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 25, 2023
Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.
Via
Benzinga
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
July 25, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Why Shares of Tarsus Pharmaceuticals Are Up Thursday
July 20, 2023
The company's lead therapy is getting close to the finish line of FDA approval.
Via
The Motley Fool
Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
July 20, 2023
Gainers PainReform Ltd. (NASDAQ: PRFX) jumped 45.5% to $10.34 after declining 8% on Wednesday. PaiReform recently regained compliance with Nasdaq continued listing requirements.
Via
Benzinga
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Climbs to New 52-Week High
July 20, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.